drugset / Trial / NCT06383052
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
NaSingle-groupOpen-labelTreatment
Summary
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
Timeline
- Start
- 2024-04-26
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NYM032 | Small molecule | 50 mbq | Intravenous |
| Subject | NYM032 | Small molecule | 200 mbq | Intravenous |